JP2019536460A5 - - Google Patents

Download PDF

Info

Publication number
JP2019536460A5
JP2019536460A5 JP2019529636A JP2019529636A JP2019536460A5 JP 2019536460 A5 JP2019536460 A5 JP 2019536460A5 JP 2019529636 A JP2019529636 A JP 2019529636A JP 2019529636 A JP2019529636 A JP 2019529636A JP 2019536460 A5 JP2019536460 A5 JP 2019536460A5
Authority
JP
Japan
Prior art keywords
immune checkpoint
cells
genetically engineered
pharmaceutical composition
engineered cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2019529636A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019536460A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/064363 external-priority patent/WO2018102786A1/en
Publication of JP2019536460A publication Critical patent/JP2019536460A/ja
Publication of JP2019536460A5 publication Critical patent/JP2019536460A5/ja
Priority to JP2023046854A priority Critical patent/JP2023078394A/ja
Withdrawn legal-status Critical Current

Links

JP2019529636A 2016-12-03 2017-12-01 Car−t細胞の調節方法 Withdrawn JP2019536460A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023046854A JP2023078394A (ja) 2016-12-03 2023-03-23 Car-t細胞の調節方法

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201662429740P 2016-12-03 2016-12-03
US62/429,740 2016-12-03
US201762444784P 2017-01-10 2017-01-10
US62/444,784 2017-01-10
US201762492950P 2017-05-01 2017-05-01
US62/492,950 2017-05-01
US201762514777P 2017-06-02 2017-06-02
US62/514,777 2017-06-02
US201762515512P 2017-06-05 2017-06-05
US62/515,512 2017-06-05
US201762549391P 2017-08-23 2017-08-23
US62/549,391 2017-08-23
US201762580414P 2017-11-01 2017-11-01
US62/580,414 2017-11-01
PCT/US2017/064363 WO2018102786A1 (en) 2016-12-03 2017-12-01 Methods for modulation of car-t cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023046854A Division JP2023078394A (ja) 2016-12-03 2023-03-23 Car-t細胞の調節方法

Publications (2)

Publication Number Publication Date
JP2019536460A JP2019536460A (ja) 2019-12-19
JP2019536460A5 true JP2019536460A5 (https=) 2021-01-21

Family

ID=60923893

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019529636A Withdrawn JP2019536460A (ja) 2016-12-03 2017-12-01 Car−t細胞の調節方法
JP2023046854A Withdrawn JP2023078394A (ja) 2016-12-03 2023-03-23 Car-t細胞の調節方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023046854A Withdrawn JP2023078394A (ja) 2016-12-03 2023-03-23 Car-t細胞の調節方法

Country Status (11)

Country Link
US (1) US20190358262A1 (https=)
EP (1) EP3548083A1 (https=)
JP (2) JP2019536460A (https=)
KR (2) KR20230156808A (https=)
CN (1) CN110248678A (https=)
AU (1) AU2017368332A1 (https=)
BR (1) BR112019011025A2 (https=)
CA (1) CA3045508A1 (https=)
MA (1) MA46961A (https=)
MX (1) MX2019006285A (https=)
WO (1) WO2018102786A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7623784B2 (ja) 2016-10-13 2025-01-29 ジュノー セラピューティクス インコーポレイテッド トリプトファン代謝経路調節剤を含む免疫療法の方法および組成物
CN118948892A (zh) * 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
PT3703750T (pt) 2017-11-01 2025-01-17 Memorial Sloan Kettering Cancer Center Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
JP7174777B2 (ja) * 2018-06-01 2022-11-17 カイト ファーマ インコーポレイテッド キメラ抗原受容体t細胞療法
EP3801619A4 (en) * 2018-06-08 2022-04-27 Atomic Energy of Canada Limited/ Énergie Atomique du Canada Limitée USING A CHECKPOINT INHIBITOR IN COMBINATION WITH ULTRA LOW DOSE WHOLE BODY IRRADIATION
CA3117978A1 (en) 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
WO2020123388A1 (en) * 2018-12-11 2020-06-18 Board Of Regents, The University Of Texas System Radiotherapies and uses thereof
AU2019397033B2 (en) 2018-12-12 2023-06-29 Kite Pharma, Inc. Chimeric antigen receptors and CAR-T cells and methods of use
CN114025775A (zh) * 2019-04-30 2022-02-08 纪念斯隆-凯特琳癌症中心 联合疗法
GB201906202D0 (en) * 2019-05-02 2019-06-19 Autolus Ltd Cell
JP2022554348A (ja) 2019-11-05 2022-12-28 ジュノー セラピューティクス インコーポレイテッド 治療用t細胞組成物の属性を決定する方法
IL292665B2 (en) 2019-11-06 2026-02-01 Kite Pharma Inc Chimeric antigen receptor T cell therapy
WO2021150919A1 (en) 2020-01-23 2021-07-29 The Children's Medical Center Corporation Stroma-free t cell differentiation from human pluripotent stem cells
KR20230024283A (ko) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
WO2026020055A2 (en) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Methods for assessing exosomes in a cell composition and related uses

Family Cites Families (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (https=) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5565566A (en) 1987-04-24 1996-10-15 Discovery Therapeutics, Inc. N6 -substituted 9-methyladenines: a new class of adenosine receptor antagonists
US5298508A (en) 1988-07-19 1994-03-29 The United States Of America As Represented By The Department Of Health And Human Services Irreversible inhibitors of adenosine receptors
US5147355A (en) 1988-09-23 1992-09-15 Brigham And Womens Hospital Cryoablation catheter and method of performing cryoablation
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5452720A (en) 1990-09-05 1995-09-26 Photoelectron Corporation Method for treating brain tumors
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5429582A (en) 1991-06-14 1995-07-04 Williams; Jeffery A. Tumor treatment
US5424297A (en) 1992-04-27 1995-06-13 University Of Virginia Alumni Patents Foundation Adenosine dextran conjugates
US5596619A (en) 1992-08-21 1997-01-21 Nomos Corporation Method and apparatus for conformal radiation therapy
DE69331692T2 (de) 1992-09-16 2002-10-24 Hitachi, Ltd. Ultraschallbestrahlungsgeraet
US5620479A (en) 1992-11-13 1997-04-15 The Regents Of The University Of California Method and apparatus for thermal therapy of tumors
US5437673A (en) 1993-02-04 1995-08-01 Cryomedical Sciences, Inc. Closed circulation tissue warming apparatus and method of using the same in prostate surgery
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
AU6781194A (en) 1993-05-03 1994-11-21 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists
IL108918A (en) 1994-03-10 1997-04-15 Medic Lightech Ltd Apparatus for efficient photodynamic treatment
US5504090A (en) 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5670501A (en) 1994-09-01 1997-09-23 Discovery Therapeutics, Inc. N-substituted 9-alkyladenines
US5549639A (en) 1994-09-16 1996-08-27 Sandia Corporation Non-invasive hyperthermia apparatus including coaxial applicator having a non-invasive radiometric receiving antenna incorporated therein and method of use thereof
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
US20020150914A1 (en) 1995-06-30 2002-10-17 Kobenhavns Universitet Recombinant antibodies from a phage display library, directed against a peptide-MHC complex
US5658234A (en) 1995-07-24 1997-08-19 J. D. Technologies, Inc. Method for treating tumors
US5776175A (en) 1995-09-29 1998-07-07 Esc Medical Systems Ltd. Method and apparatus for treatment of cancer using pulsed electromagnetic radiation
CA2244774C (en) 1996-01-29 2006-10-17 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dihydropyridine derivatives, their preparation and their use as adenosine receptor antagonists
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
US5654279A (en) 1996-03-29 1997-08-05 The Regents Of The University Of California Tissue destruction in cryosurgery by use of thermal hysteresis
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
DE122007000079I2 (de) 1996-07-24 2010-08-12 Celgene Corp Substituierte 2-(2,6-dioxopiperidin-3-yl)-phthalimide und -1-oxoisoindoline und verfahren zur reduzierung des tnf-alpha-spiegels
DE69737508T2 (de) 1996-10-24 2007-11-29 The Nomos Corp. Methode zur planung und vorrichtung zur planung der bestrahlungsdosierung
US5786360A (en) 1996-11-19 1998-07-28 Link Technology Incorporated A1 adenosine receptor antagonists
EP0897731A4 (en) 1996-11-26 2003-07-30 Mitsubishi Electric Corp METHOD FOR CHANGING THE POWER DISTRIBUTION
AU6874098A (en) 1997-04-02 1998-10-22 Wound Healing Of Oklahoma, Inc. Laser light delivery system and method
US6027499A (en) 1997-05-23 2000-02-22 Fiber-Tech Medical, Inc. (Assignee Of Jennifer B. Cartledge) Method and apparatus for cryogenic spray ablation of gastrointestinal mucosa
US6165440A (en) 1997-07-09 2000-12-26 Board Of Regents, The University Of Texas System Radiation and nanoparticles for enhancement of drug delivery in solid tumors
US6009351A (en) 1997-07-14 1999-12-28 Urologix, Inc. System and method for transurethral heating with rectal cooling
ATE533784T1 (de) 1997-10-02 2011-12-15 Altor Bioscience Corp Lösliche, einzelkettige proteine des t- zellrezeptors
US6015541A (en) 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US5885276A (en) 1997-12-02 1999-03-23 Galil Medical Ltd. Method and device for transmyocardial cryo revascularization
JP3053389B1 (ja) 1998-12-03 2000-06-19 三菱電機株式会社 動体追跡照射装置
TW496741B (en) 1998-03-12 2002-08-01 Dept Of Health R O C Radioactive particles and method for producing the same
TR200101502T2 (tr) 1998-03-16 2002-06-21 Celgene Corporation 2-(2,6-dioksopiperidin-3-il) izoindolin türevleri, bunların hazırlanması ve enflamatuar sitokinlerin inhibitörleri olarak kullanımı
ES2246567T3 (es) 1998-04-15 2006-02-16 Brigham & Womens Hospital Composiciones para receptores inhibidores de celulas t y usos de las mismas.
WO1999060120A2 (en) 1998-05-19 1999-11-25 Avidex Limited Soluble t cell receptor
US6001054A (en) 1998-05-19 1999-12-14 Regulla; D. F. Method and apparatus for differential energy application for local dose enhancement of ionizing radiation
US6393096B1 (en) 1998-05-27 2002-05-21 Nomos Corporation Planning method and apparatus for radiation dosimetry
EP0960601B1 (en) 1998-05-28 2006-10-11 Terumo Kabushiki Kaisha Tissue irradiation apparatus
US6326390B1 (en) 1998-08-25 2001-12-04 King Pharmaceuticals Reseach And Development, Inc. Use of adenosine A3 receptor antagonists to inhibit tumor growth
EP1109921A4 (en) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF
US6163726A (en) 1998-09-21 2000-12-19 The General Hospital Corporation Selective ablation of glandular tissue
US6335961B1 (en) 1998-10-06 2002-01-01 Siemens Medical Systems, Inc. Integrated high definition intensity multileaf collimator system which provides improved conformal radiation therapy while minimizing leakage
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
WO2000040299A1 (en) 1999-01-06 2000-07-13 Ball Semiconductor, Inc. Radiation dosimetry system
US6569158B1 (en) 1999-01-25 2003-05-27 Cryocath Technologies, Inc. Leak detection system
US6179766B1 (en) 1999-01-28 2001-01-30 Gregg A. Dickerson Methods of breast cancer treatment
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6313131B1 (en) 1999-02-16 2001-11-06 Upsher-Smith Laboratories, Inc. Method of kidney treatment
CN1342146A (zh) 1999-03-18 2002-03-27 塞尔基因公司 取代的1-氧代-和1,3-二氧代异吲哚啉及其在用于减少炎性细胞因子含量的药物组合物中的用途
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
US6245005B1 (en) 1999-07-16 2001-06-12 International Business Machines Corporation Method and apparatus for facilitating radiation treatment of deep tumors
US6319189B1 (en) 1999-09-13 2001-11-20 Isotron, Inc. Methods for treating solid tumors using neutron therapy
US20040191260A1 (en) 2003-03-26 2004-09-30 Technion Research & Development Foundation Ltd. Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof
US6470217B1 (en) 2000-04-13 2002-10-22 Celsion Corporation Method for heating ductal and glandular carcinomas and other breast lesions to perform thermal downsizing and a thermal lumpectomy
US6449336B2 (en) 2000-05-19 2002-09-10 Siyong Kim Multi-source intensity-modulated radiation beam delivery system and method
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (de) 2000-11-07 2006-09-15 Hope City Cd19-spezifische umgezielte immunzellen
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
EP1465634B1 (en) 2001-12-12 2014-10-22 The Government of the United States of America, as represented by the Secretary Department of Health and Human Services Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
US6992176B2 (en) 2002-02-13 2006-01-31 Technion Research & Development Foundation Ltd. Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease
AU2003216341A1 (en) 2002-02-20 2003-09-09 Dyax Corporation Mhc-peptide complex binding ligands
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20040047858A1 (en) 2002-09-11 2004-03-11 Blumberg Richard S. Therapeutic anti-BGP(C-CAM1) antibodies and uses thereof
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
AU2005247950B2 (en) 2004-05-27 2012-02-02 Receptor Logic, Inc. Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090226474A1 (en) 2004-05-27 2009-09-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090304679A1 (en) 2004-05-27 2009-12-10 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
ATE475669T1 (de) 2004-06-29 2010-08-15 Immunocore Ltd Einen modifizierten t-zellen-rezeptor exprimierende zellen
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
PT1907424E (pt) 2005-07-01 2015-10-09 Squibb & Sons Llc Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1)
EP2111231A4 (en) 2007-02-13 2010-12-15 Univ Northeastern METHOD AND COMPOSITIONS FOR IMPROVING IMMUNE REACTIONS
SI2856876T1 (en) 2007-03-30 2018-04-30 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2212350B1 (en) 2007-10-26 2013-08-28 Governing Council of the University of Toronto Treating chronic viral infection by targetting TIM-3
ES2660180T3 (es) 2007-12-07 2018-03-21 Miltenyi Biotec Gmbh Sistemas y métodos para procesamiento de células
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
CN101970499B (zh) 2008-02-11 2014-12-31 治疗科技公司 用于肿瘤治疗的单克隆抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
GB0906579D0 (en) 2009-04-16 2009-05-20 Vernalis R&D Ltd Pharmaceuticals, compositions and methods of making and using the same
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
JP2012500855A (ja) 2008-08-25 2012-01-12 アンプリミューン、インコーポレーテッド Pd−1アンタゴニストおよび感染性疾患を処置するための方法
AU2009288730B2 (en) 2008-08-25 2013-06-20 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use
EP2331566B1 (en) 2008-08-26 2015-10-07 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010065959A1 (en) 2008-12-05 2010-06-10 Northeastern University Method of preparing adenosine-resistant anti-tumor t lymphocytes for adoptive immunotherapy
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille Pd−1抗体およびpd−l1抗体ならびにその使用
KR20180077322A (ko) 2009-04-30 2018-07-06 텔 하쇼머 메디컬 리서치 인프라스트럭쳐 앤드 서비시스 리미티드. 항-ceacam1 항체들과 이를 이용하는 방법들
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
TR201904484T4 (tr) 2009-11-03 2019-05-21 Hope City Transdüse T hücre seçimine yönelik kesik epiderimal büyüme faktörü reseptörü (EGFRt).
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9987308B2 (en) 2011-03-23 2018-06-05 Fred Hutchinson Cancer Research Center Method and compositions for cellular immunotherapy
MX2013011363A (es) 2011-04-01 2014-04-25 Sloan Kettering Inst Cancer Anticuerpos para peptidos citosolicos.
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
WO2013054320A1 (en) 2011-10-11 2013-04-18 Tel Hashomer Medical Research Infrastructure And Services Ltd. Antibodies to carcinoembryonic antigen-related cell adhesion molecule (ceacam)
CN104080797A (zh) 2011-11-11 2014-10-01 弗雷德哈钦森癌症研究中心 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-pd-l1 항체 및 그의 용도
US9556271B2 (en) 2011-12-01 2017-01-31 The Brigham And Women's Hospital, Inc. Anti-CEACAM1 recombinant antibodies for cancer therapy
EP2804625A4 (en) 2012-01-17 2015-10-28 Univ Northeastern METHOD AND COMPOSITIONS FOR THE EXPANSION OF IMMUNOSUPPRESSIVE REGULATORY T CELLS IN VITRO AND USES THEREOF
CA2861491C (en) 2012-02-13 2020-08-25 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
EP2844743B1 (en) 2012-05-03 2021-01-13 Fred Hutchinson Cancer Research Center Enhanced affinity t cell receptors and methods for making the same
WO2014022332A1 (en) 2012-07-31 2014-02-06 The Brigham And Women's Hospital, Inc. Modulation of the immune response
BR122020002986A8 (pt) 2012-08-20 2023-04-18 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapia celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
HK1213788A1 (zh) 2012-10-12 2016-07-15 布里格姆及妇女医院股份有限公司 免疫應答的增强
CN104781789B (zh) 2012-12-20 2018-06-05 三菱电机株式会社 车载装置
UY35468A (es) 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
WO2015085172A2 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
NZ759969A (en) 2013-12-20 2022-12-23 Fred Hutchinson Cancer Center Tagged chimeric effector molecules and receptors thereof
PE20170255A1 (es) 2014-01-24 2017-03-22 Dana Farber Cancer Inst Inc Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
KR102442436B1 (ko) 2014-03-14 2022-09-15 노파르티스 아게 Lag-3에 대한 항체 분자 및 그의 용도
US20170335281A1 (en) * 2014-03-15 2017-11-23 Novartis Ag Treatment of cancer using chimeric antigen receptor
CN113604491A (zh) 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 嵌合自身抗体受体t细胞的组合物和方法
KR20170068504A (ko) * 2014-10-08 2017-06-19 노파르티스 아게 키메라 항원 수용체 요법에 대한 치료 반응성을 예측하는 바이오마커 및 그의 용도
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)

Similar Documents

Publication Publication Date Title
JP2019536460A5 (https=)
Wang et al. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
JP7656012B2 (ja) 肺癌の処置のための抗pd-1抗体
Yonezawa et al. Boosting cancer immunotherapy with anti-CD137 antibody therapy
JP7054680B2 (ja) Pd-1阻害剤を投与することによって皮膚がんを処置する方法
EP3157629B1 (en) Methods of cancer treatment with antagonists against pd-1 and pd-l1 in combination with radiation therapy
US20190358262A1 (en) Methods for modulation of car-t cells
JP2019532997A5 (https=)
Freeman et al. Immunotherapy in chronic lymphocytic leukaemia (CLL)
KR20180012851A (ko) 고 친화성 및 고 특이성을 가진 tcr-유사 항체 결합 도메인을 포함하는 친화성 엔티티 및 이의 용도
WO2019114762A1 (zh) 免疫效应细胞和辐射联用治疗肿瘤
Yang et al. Combinations of radiotherapy with immunotherapy in cervical cancer
De Felice et al. Immune check-point in glioblastoma multiforme
Cohen et al. Therapeutic combinations of immune-modulating antibodies in melanoma and beyond
WO2022130206A1 (en) TGFβr1 INHIBITOR COMBINATION THERAPIES
US11564987B2 (en) Combination immunotherapy for treatment of triple-negative breast cancer
EP4588481A1 (en) Composition for preventing or treating cancer, and method for preventing or treating cancer by using same, having abscopal effect
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
Marzolini et al. Checkpoint blockade in cancer immunotherapy: squaring the circle
Myers et al. Overcoming Cancer Tolerance with Immune Checkpoint Blockade
WO2024204688A1 (ja) 医薬
Padda et al. Tumor immunology
Kato Therapeutic Monoclonal Antibodies for Cancer: The Past, Present, and Future
Chacko et al. ROLE OF SINGLE IMMUNO-ONCOLOGY AGENTS AND COMBINATIONS IN CANCER THERAPY
JP2023538568A (ja) がん治療における使用のためのlfa-1シグナル伝達メディエーター